Denosumab (Prolia) is a human monoclonal antibody which inhibits RANK ligand activation of osteoclasts, inhibiting bone breakdown. In 2010 it was approved by the FDA for use in post-menopausal women at risk for osteoporosis, and has evidence that it reduces fractures of both spine and hip. It is given sub-cutaneously twice yearly in a healthcare setting (not for home use). Significant side effects include hypocalcemia and softer tissue infections. The cost is $1800 per year.
Denosumab (Prolia) 60 mg SQ twice yearly